25T7-NBOMe

25T7-NBOMe is a psychedelic drug and a derivative of the phenethylamine family. It is closely related to the better-known 25I-NBOMe and 25C-NBOMe, and was first synthesized by the team led by David E. Nichols at Purdue University. It is part of the NBOMe series of psychedelic phenethylamines, specifically, it is the 2,5-dimethoxy-4-(n)-propylthiophenethylamine.

Chemistry

25T7-NBOMe is a derivative of the 2C family of phenethylamines described by Alexander Shulgin in his book PiHKAL. The full name of the chemical is 2-(2,5-Dimethoxy-4-(propylthio)phenyl)-N-[(2-methoxyphenyl)methyl]ethanamine. It belongs to the NBOMe series, which includes other psychedelic substances like 25I-NBOMe and 25C-NBOMe. The NBOMe series is characterized by the addition of a 2-methoxybenzyl (NBOMe) group to the phenethylamine backbone. This modification significantly increases the potency of the base compound.

Pharmacology

The pharmacology of 25T7-NBOMe is not fully understood. Like other compounds in the NBOMe series, it is thought to act as a highly potent partial agonist for the 5-HT2A receptor, a subtype of the serotonin receptor. The 5-HT2A receptor is known to play a key role in the cognitive effects of many psychedelics.

Effects

The effects of 25T7-NBOMe can vary greatly depending on the dose, set, and setting. Common effects reported by users include intense visual hallucinations, euphoria, a sense of unity and interconnectedness, and altered thought patterns. However, the drug can also cause negative effects such as anxiety, paranoia, and potentially dangerous increases in heart rate and blood pressure.

Legality

The legality of 25T7-NBOMe varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and the health risks associated with its use.

See also

• 25I-NBOMe
• 25C-NBOMe
• Psychedelic drug
• Phenethylamine
• NBOMe series